Cancer treatment suffers from one of the lowest success hit rates among major diseases. Permanent remission or even for 20, 30 years scores are very low. And in terms of return on the spend on treatment, the ratios can be abysmally low. The treatment, even with newer drugs being introduced from time to time, has largely remained monolithic based on the theory of cellular divisions gone wrong. Even though the fact is now well recognised that cancer is largely a metabolic disease and can have several mechanisms of its perseverance, different treatment approaches like repurposed drugs have not gone main stream. Dr Flora often writes that oncologists are open, but one cannot see it in reality. Good amount of repurposed work has happened and with much better success rates than the conventional treatments like chemo. New generation drugs like monoclonal antibody drugs may be more successful, but the costs are too heavy. Both from the angle of widespread affordability and better effectiveness, oncologists have to bring repurposed drugs mainstream. For a start as integrated treatments where they support conventional methods. Such approaches have to bypass conventional studies which examine both effectiveness and usage safety. With repurposed drugs, the safety is already well established in the use of their primary indications. Cancer care has to undergo a major metamorphosis, not just on technical grounds, but on social grounds also.